tbuckley/cabot-search huggingface dataset:
Erlotinib<i>versus</i>carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504
Authors: Jacques Cadranel, Radj Gervais, Patrick Merle, Denis Moro-Sibilot, Virginie Westeel, Laurence Bigay-Game, Elisabeth Quoix, Sylvie Friard, Fabrice Barlesi, Claire Lethrosne, Lionel Moreau, Isabelle Monnet, Mathieu Salaun, Gérard Oliviero, Pierre-Jean Souquet, Martine Antoine, Alexandra Langlais, Franck Morin, Marie Wislez, Gérard Zalcman
Journal: European Respiratory Journal (2015)

The IFCT-0504 phase II trial evaluated the efficacy of erlotinib versus carboplatin-paclitaxel (CP) as first-line treatment in 130 cases of advanced lepidic-predominant adenocarcinoma (ADC).The primary objective of the study was treatment efficacy, evaluated based on an end-point of disease control at 16 weeks.The primary objective was met, with a disease control in 35 (53%) out of 66 patients treated with CP and in 25 (39.1%) out of 64 patients treated with erlotinib. Median progression-free survival (PFS) for the total population was 3.6 months. The disease control rate did not differ between either the therapeutic arms or pathological subtypes, whereas there was a strong interaction between treatment arms and tumour pathological subtypes for PFS (p=0.009). Mucinous tumour patients treated with erlotinib exhibited an increased progression risk (hazard ratio 3.4, 95% CI 1.7-6.5; p≤0.001). The PFS for nonmucinous tumour patients was similar in both arms. Median overall survival was 20.1 months and did not differ between therapeutic arms. These findings were not further elucidated by molecular analyses and the toxicity profiles were as expected.Our study demonstrated the dominant role of CP alongside erlotinib in the management of advanced lepidic ADC. Based on these findings, erlotinib should not be administered in first-line therapy to patients with lepidic ADC in the absence of an epidermal growth factor receptor mutation.
Evaluation and Regulation of Oncology Drug Approval
Authors: Gary H. Lyman
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Incremental prognostic value of coronary artery disease and renal function on the prediction of cardiovascular events of patients evaluated by coronary computed tomography: the partners registry
Authors: Márcio Sommer Bittencourt, Edward A. Hulten, Suhny Abbara, Brian Ghoshhajra, Venkatesh L. Murthy, Quynh A. Truong, Luis Henrique W. Gowdak, Leonardo V. Riella, Marcelo Di Carli, Udo Hoffmann, Ron Blankstein
Journal: Circulation (2013)

Apresentado no Scientific Sessions and Resuscitation Science Symposium of the American Heart Association, realizado em 16-17 de novembro de 2013 em Dallas, TX.
False Positive Tests for HTLV-III Antibodies in Alcoholic Patients with Hepatitis
Authors: C L Mendenhall, G A Roselle, C J Grossman, S D Rouster, R E Weesner
Journal: New England Journal of Medicine (1986)

Serum from 95 patients with acute alcoholic hepatitis was analyzed by enzyme immunoassay and (if positive) by Western blot for human T-lymphotropic virus type III (HTLV-III) antibodies.  Patients who had a current history of drug abuse or positive tests for hepatitis B virus surface antigen were excluded.  Clinically severe liver disease was present in 31 patients moderate disease in 34 and mild disease in 30.  Anergy was observed in 60 patients and an adequate delayed cutaneous hypersensitivity response was observed in 34 patients.  Although hepatitis B surface antigenemia on admission was a reason for exclusion from the study antibodies to the hepatitis B surface antigen the core antigen or both were observed in 31% of the samples.  Of the 95 patients 13% were positive for HTLV-III antibody by the enzyme immunoassay.  However all of these samples were negative by the Western blot assessment.  The incidence of unconfirmed positive results on the less specific immunoassay observed in these alcoholic patients with hepatitis (13%) stands in contrast to the incidence of 0.89% among blood donors in general.  These findings demonstrate that patients with alcoholic liver disease have a high incidence of false positives on tests for HTLV-III antibodies.  This is important to recognize so that these patients are not falsely identified as having previous infection with HTLV-III.
Academic Outcomes 2 Years After Working Memory Training for Children With Low Working Memory
Authors: Gehan Roberts, Jon Quach, Megan Spencer-Smith, Peter J. Anderson, Susan Gathercole, Lisa Gold, Kah-Ling Sia, Fiona Mensah, Field Rickards, John Ainley, Melissa Wake
Journal: JAMA Pediatrics (2016)

Working memory training may help children with attention and learning difficulties, but robust evidence from population-level randomized controlled clinical trials is lacking.To test whether a computerized adaptive working memory intervention program improves long-term academic outcomes of children 6 to 7 years of age with low working memory compared with usual classroom teaching.Population-based randomized controlled clinical trial of first graders from 44 schools in Melbourne, Australia, who underwent a verbal and visuospatial working memory screening. Children were classified as having low working memory if their scores were below the 15th percentile on either the Backward Digit Recall or Mister X subtest from the Automated Working Memory Assessment, or if their scores were below the 25th percentile on both. These children were randomly assigned by an independent statistician to either an intervention or a control arm using a concealed computerized random number sequence. Researchers were blinded to group assignment at time of screening. We conducted our trial from March 1, 2012, to February 1, 2015; our final analysis was on October 30, 2015. We used intention-to-treat analyses.Cogmed working memory training, comprising 20 to 25 training sessions of 45 minutes' duration at school.Directly assessed (at 12 and 24 months) academic outcomes (reading, math, and spelling scores as primary outcomes) and working memory (also assessed at 6 months); parent-, teacher-, and child-reported behavioral and social-emotional functioning and quality of life; and intervention costs.Of 1723 children screened (mean [SD] age, 6.9 [0.4] years), 226 were randomized to each arm (452 total), with 90% retention at 1 year and 88% retention at 2 years; 90.3% of children in the intervention arm completed at least 20 sessions. Of the 4 short-term and working memory outcomes, 1 outcome (visuospatial short-term memory) benefited the children at 6 months (effect size, 0.43 [95% CI, 0.25-0.62]) and 12 months (effect size, 0.49 [95% CI, 0.28-0.70]), but not at 24 months. There were no benefits to any other outcomes; in fact, the math scores of the children in the intervention arm were worse at 2 years (mean difference, -3.0 [95% CI, -5.4 to -0.7]; P = .01). Intervention costs were A$1035 per child.Working memory screening of children 6 to 7 years of age is feasible, and an adaptive working memory training program may temporarily improve visuospatial short-term memory. Given the loss of classroom time, cost, and lack of lasting benefit, we cannot recommend population-based delivery of Cogmed within a screening paradigm.anzctr.org.au Identifier: ACTRN12610000486022.
Reducing Phthalate, Paraben, and Phenol Exposure from Personal Care Products in Adolescent Girls: Findings from the HERMOSA Intervention Study
Authors: Kim G. Harley, Katherine Kogut, Daniel S. Madrigal, Maritza Cardenas, Irene A. Vera, Gonzalo Meza-Alfaro, Jianwen She, Qi Gavin, Rana Zahedi, Asa Bradman, Brenda Eskenazi, Kimberly L. Parra
Journal: Environmental Health Perspectives (2016)

Personal care products are a source of exposure to potentially endocrine-disrupting chemicals such as phthalates, parabens, triclosan, and benzophenone-3 (BP-3) for adolescent girls.We enrolled 100 Latina girls in a youth-led, community-based participatory research intervention study to determine whether using personal care products whose labels stated they did not contain these chemicals for 3 days could lower urinary concentrations. Pre- and postintervention urine samples were analyzed for phthalate metabolites, parabens, triclosan, and BP-3 using high-performance liquid chromatography/tandem mass spectrometry.Urinary concentrations of mono-ethyl phthalate (MEP) decreased by 27.4% (95% CI: -39.3, -13.2) on average over the 3-day intervention; no significant changes were seen in urinary concentrations of mono-n-butyl phthalate (MnBP) and mono-isobutyl phthalate (MiBP). Methyl and propyl paraben concentrations decreased by 43.9% (95% CI: -61.3, -18.8) and 45.4% (95% CI: -63.7, -17.9), respectively. Unexpectedly, concentrations of ethyl and butyl paraben concentrations increased, although concentrations were low overall and not detected in almost half the samples. Triclosan concentrations decreased by 35.7% (95% CI: -53.3, -11.6), and BP-3 concentrations decreased by 36.0% (95% CI: -51.0, -16.4).This study demonstrates that techniques available to consumers, such as choosing personal care products that are labeled to be free of phthalates, parabens, triclosan, and BP-3, can reduce personal exposure to possible endocrine-disrupting chemicals. Involving youth in the design and implementation of the study was key to recruitment, retention, compliance, and acceptability of the intervention.Harley KG, Kogut K, Madrigal DS, Cardenas M, Vera IA, Meza-Alfaro G, She J, Gavin Q, Zahedi R, Bradman A, Eskenazi B, Parra KL. 2016. Reducing phthalate, paraben, and phenol exposure from personal care products in adolescent girls: findings from the HERMOSA Intervention Study. Environ Health Perspect 124:1600-1607; http://dx.doi.org/10.1289/ehp.1510514.
A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy
Authors: Y. Merrouche, G. Catimel, P. Rebattu, A. Dumortier, J.P. Guastalla, M. Clavel, P. O'Grady
Journal: Annals of Oncology (1994)
Clinicians will get legal protection for owning up to mistakes
Authors: Adrian O’Dowd
Journal: BMJ (2016)

Clinicians have been promised legal protection from being prosecuted or disciplined if they speak up about mistakes made at work, under a new patient safety drive in England. The Department of Health’s plan will also create a team of expert medical examiners to review the cause of all NHS patient deaths.

Doctors’ leaders have welcomed the drive for better transparency, but they warned that the reforms must be properly resourced to overcome the current “oppressive, management driven culture in the NHS” that can deter openness.

England’s health secretary, Jeremy Hunt, announced plans to improve NHS safety and transparency at a ministerial level global patient safety summit, held in London on 9 and 10 March. …
The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials
Authors: Robert K. Hills, Stephen Petersdorf, Elihu H. Estey, Megan Othus, Frederick R. Appelbaum, Sylvie Castaigne, Herve Dombret, Sylvie Chevret, Jacques Delaunay, Norbert Ifrah, Jean-Yves Cahn, Christian Recher, Alan K Burnett
Journal: Blood (2013)
Plasmid-mediated colistin resistance (mcr-1 gene): three months later, the story unfolds
Authors: Robert L. Skov, Dominique L. Monnet
Journal: Eurosurveillance (2016)

Preview this article: Plasmid-mediated colistin resistance (mcr-1 gene): three months later, the story unfolds, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/21/9/eurosurv-21-30155-1-1.gif
Impaired Expression of Integrin -4 Subunit in Cultured Mast Cells Derived From Mutant Mice of mi/mi Genotype
Authors: Dae-Ki Kim, Eiichi Morii, Hideki Ogihara, Koji Hashimoto, Kenji Oritani, Young-Mi Lee, Tomoko Jippo, Shiro Adachi, Yuzuru Kanakura, Yukihiko Kitamura
Journal: Blood (1998)
Cyclooxygenase-2 expression in renal cell neoplasms
Authors: M. Kota, R. Shah, J. James, M. Kohli, G. Greene, A. M. Maddox, N. Gokden
Journal: Journal of Clinical Oncology (2004)

9699 Background: Cyclooxygenase-2 (Cox-2) is over-expressed in various malignancies during tumorigenesis and cancer progression. Expression of this protein has not been well studied in renal cell neoplasms (RCN). We conducted a study in archival tissue for Cox-2 expression in RCN. Methods: Immunohistochemical analysis was performed on 20 paraffin-embedded specimens of resected RCN, (11 clear cell renal cell carcinomas (RCC), 5 papillary RCC, 2 Chromophobe RCC, and 2 oncocytomas) using commercially available monoclonal antibody against Cox-2 (C295, Rabbit IgG, Immuno-Biological Laboratories Co., Naka, Japan). Positive and negative controls were used. The staining intensity was semiquantitatively graded as 1+ to 3+. We previously tried staining with another antibody against Cox-2 (Santa Cruz Biotechnology, Inc. ) and the results were negative. Results: Seven specimens [5 RCC,(2 clear cell, 2 Papillary, 1 chromophobe) and 2 oncocytoma] showed 3+positivity for Cox-2 in a patchy distribution with the C 295 antibody. Staining was cytoplasmic and membranous in the clear cell and chromophobe variants of RCC and cytoplasmic only in the remaining. Cox-2 expression by histology, tumor grade and stage is tabulated. (Table 1) Conclusions: This study shows that Cox-2 protein is expressed in a subset of renal neoplasms. The patchy distribution of staining may be due to tumor heterogeneity. Additional studies are planned to expand the sample set, and to define any correlation of Cox-2 expression in RCN with tumor grade, or stage. The reason for negative results with the first antibody (Santa Cruz) is unclear. Patients with Cox-2 expressing tumors may benefit from Cox-2 inhibitors and this should be explored in future clinical trials. No significant financial relationships to disclose.
OsSPL13 controls grain size in cultivated rice
Authors: Lizhen Si, Jiaying Chen, Xuehui Huang, Hao Gong, Jianghong Luo, Qingqing Hou, Taoying Zhou, Tingting Lu, Jingjie Zhu, Yingying Shangguan, Erwang Chen, Chengxiang Gong, Qiang Zhao, Yufeng Jing, Yan Zhao, Yan Li, Lingling Cui, Danlin Fan, Yiqi Lu, Qijun Weng, Yongchun Wang, Qilin Zhan, Kunyan Liu, Xinghua Wei, Kyungsook An, Gynheung An, Bin Han
Journal: Nature Genetics (2016)
Explaining the success of karmic religions
Authors: Claire White, Paulo Sousa, Karolina Prochownik
Journal: Behavioral and Brain Sciences (2016)

Abstract One of the central claims of Norenzayan et al.’s article is that supernatural monitoring and intergroup competition have facilitated the rise of large-scale prosocial religions. Although the authors outline in detail how social instincts that govern supernatural monitoring are honed by cultural evolution and have given rise to Big Gods, they do not provide a clear explanation for the success of karmic religions. Therefore, to test the real scope of their model, Norenzayan et al. need to seriously engage with questions concerning the evolution of karmic prosocial religions.
Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors
Authors: H.J.G. Abrahams, M.F.M. Gielissen, I.C. Schmits, C.A.H.H.V.M. Verhagen, M.M. Rovers, H. Knoop
Journal: Annals of Oncology (2016)
Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C
Authors: R J Lin, T Moskovits, C S Diefenbach, K B Hymes
Journal: Blood Cancer Journal (2016)

Previous clinical epidemiological studies have demonstrated an increased risk of B-cell lymphoproliferative disorders in patients with chronic hepatitis C virus (HCV) infection. 1The most common B-cell non-Hodgkin's lymphoma associated with HCV is marginal zone lymphoma (MZL), including splenic and extranodal (mainly non-gastric) forms.However, associations with mucosa-associated lymphoid tissue lymphoma, lymphoplasmacytic lymphoma (LPL) and diffuse large B-cell lymphoma (DLBCL) have also been reported, although an association between HCV and mantle cell lymphoma (MCL) is uncommon. 1These observations were substantiated by the EPILYMPH study that identified DLBCL, MZL and LPL as most frequently associated with HCV infection. 2Furthermore, the large International Lymphoma Epidemiology Consortium (InterLymph) case-control study quantified the lymphoma risk associated with HCV infection as follows: DLBCL (odds ratio (OR) = 2.24)), MZL (OR = 2.47) and LPL (OR = 2.57). 3espite these findings, a causal relationship between HCV infection and lymphoma remains unclear, confounded by factors, such as the method of HCV assessment, the selection of normal controls and the classification of lymphoproliferative disorders. 4,58][9] Here, we described the novel finding of two patients who presented with aggressive MCL in the context of clearance of chronic HCV infection.The first patient was a 69-year-old Caucasian male Podiatrist with hypertension, and newly diagnosed HCV who had completed 12 weeks of sofosbuvir/ribavirin treatment in December 2014.One month later he presented with progressive anorexia, weight loss and lower extremity weakness.No contributory family or social history was elicited.On admission, he had diffuse lymphadenopathy, massive hepatosplenomegaly, bilateral lower extremity erythematous rash and spinal cord compression.Laboratory studies were notable for a whilte blood cells 13.7 with 35% monocytes, hemoglobin of 9.7, platelet of 386, elevated lactate dehydrogenase of 5872 and elevated uric acid of 13.3 with acute kidney injury with creatinine of 2.8.HCV viral load was undetectable and liver function tests were within normal limits.Human immunodeficiency virus/epstein-barr virus/cytomegalovirus (HIV/EBV/CMV) serology was negative.Skin biopsy showed leukocytoclastic vasculitis.Lymph node biopsy revealed a 'doublehit' blastic MCL with cyclin D1 (t11;14) and c-Myc (t8;14) translocation.Ki-67 proliferation index exceeded 90%.He was being treated with R-hyperCVAD regimen with partial response.The second patient was a 61-year-old Hispanic male with chronic hepatitis C and cirrhosis who had failed previous interferon treatments but completed 24 weeks of sofosbuvir/ ribavirin treatment resulting in clearance of HCV viral load in July 2014.Within 1 month, he developed progressive anorexia, weight loss and night sweats along with increased inguinal lymph nodes.
Modulation of neutrophil functionalities by indacaterol and their relevance for chronic lung diseases
Authors: Martina Bakele, Irina Winckler, Andreas Hector, Dominik Hartl
Journal: European Respiratory Journal (2014)

Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), severe asthma and cystic fibrosis (CF), are characterized by an infiltration of neutrophils into the airways. Long-acting inhaled bronchodilators (long-acting β2-agonists, LABAs) in a regularly scheduled regimen are recommended as first-line therapy in symptomatic patients with COPD. Traditionally, a potential effect of LABAs on neutrophils has been rather neglected. Recent studies, however, revealed that LABAs may represent key modulators of neutrophil effector responses by exerting a “neutrophil-stabilising” effect, but the underlying modes of actions, in particular in the context of COPD, are poorly understood. Therefore, we comprehensively studied the effect of the LABA indacaterol on homeostasis and effector functionalities of human neutrophils. These studies demonstrate that indacaterol modulates neutrophilic surface marker expression profiles, particularly downregulates CD11b/integrin surface expression, while upregulating CD62L and preventing PMA-induced CD62L shedding. These results were validated by analysing the effect of indacaterol on COPD airway fluid-induced neutrophil activation. These studies confirmed the “neutrophil dampening” effect of indacaterol. At the cellular level, indacaterol did not impair the anti-bacterial neutrophil functions, such as phagocytosis or granule release. When viewed in combination, these data support the notion that indacterol modulates neutrophilic inflammation by dampening, but not impairing, neutrophil responses, which may have implications for the neutrophilic inflammation in COPD and other chronic lung diseases.
Moralizing religions: Prosocial or a privilege of wealth?
Authors: Scott Atran
Journal: Behavioral and Brain Sciences (2016)

Abstract Today's major religions are moralizing religions that encourage material sacrifice for spiritual rewards. A key issue is whether moralizing religions gradually evolved over several millennia to enable cooperation among genetic strangers in the spiraling competition between increasingly large groups occupying Eurasia's middle latitudes, or whether they emerged only with the onset of the Axial Age, about 2,500 years ago, as societal wealth increased to allow privileging long-term goals over immediate needs.